Lumexa Imaging Holdings, Inc. filings document the public-company record for a Nasdaq-listed outpatient medical imaging provider. The company’s disclosures cover its common stock, completed initial public offering, registration statement history, stockholder agreements and capital-structure matters.
LMRI regulatory filings include definitive proxy materials for annual meeting votes and governance matters, Form 8-K reports on financial results, Regulation FD updates, executive transition and compensation arrangements, and material financing agreements. Debt-related filings describe the company’s senior secured credit facility, revolving credit arrangements, maturity terms, interest-rate framework and restrictive covenants affecting operating subsidiaries.
Lumexa Imaging Holdings director-related trust buys shares
Cooper Family Trust, a revocable trust for which director Cooper Henry Lee and his spouse serve as co-trustees, purchased 30,000 shares of Lumexa Imaging Holdings, Inc. common stock in an open-market transaction at a weighted average price of $7.4371 per share on May 14, 2026.
Following the purchase, the trust holds 30,000 shares indirectly attributed to Lee. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Lumexa Imaging Holdings reported Q1 2026 total revenues of $252.5M, up from $245.0M a year earlier, driven by outpatient and professional imaging services. Net income was $1.7M, compared with a net loss of $7.7M in Q1 2025, with basic and diluted EPS of $0.02 versus $(0.11).
Operating cash flow improved to $2.9M from a use of $14.0M, while cash and cash equivalents ended at $51.2M. Long-term debt remained significant at $816.97M (excluding current portion), largely from a senior secured term loan. Adjusted EBITDA was $51.2M, essentially flat year over year.
The company operated 189 outpatient imaging centers across 13 states as of March 31, 2026, including 103 consolidated centers and 86 joint-venture centers accounted for under the equity method. Commercial payors provided 57% of consolidated net patient service revenue, with Medicare and Medicaid contributing another 28%.
Lumexa Imaging Holdings reported Q1 2026 total revenues of $252.5M, up from $245.0M a year earlier, driven by outpatient and professional imaging services. Net income was $1.7M, compared with a net loss of $7.7M in Q1 2025, with basic and diluted EPS of $0.02 versus $(0.11).
Operating cash flow improved to $2.9M from a use of $14.0M, while cash and cash equivalents ended at $51.2M. Long-term debt remained significant at $816.97M (excluding current portion), largely from a senior secured term loan. Adjusted EBITDA was $51.2M, essentially flat year over year.
The company operated 189 outpatient imaging centers across 13 states as of March 31, 2026, including 103 consolidated centers and 86 joint-venture centers accounted for under the equity method. Commercial payors provided 57% of consolidated net patient service revenue, with Medicare and Medicaid contributing another 28%.
Lumexa Imaging Holdings, Inc. reported a first-quarter 2026 profit and reiterated its full-year 2026 guidance. Total revenues rose to $252.5M from $245.0M, driven by higher outpatient imaging volumes and a greater mix of advanced procedures.
Net income improved to $1.7M, or $0.02 per diluted share, compared with a net loss of $7.7M, or $(0.11) per share, a year earlier. Adjusted EBITDA was stable at $51.2M, while adjusted diluted earnings per share increased to $0.18 from $0.04. System-wide total procedures grew, with advanced procedures expanding faster than overall volumes, supporting management’s view of sustained, profitable growth.
Lumexa Imaging Holdings, Inc. reported a first-quarter 2026 profit and reiterated its full-year 2026 guidance. Total revenues rose to $252.5M from $245.0M, driven by higher outpatient imaging volumes and a greater mix of advanced procedures.
Net income improved to $1.7M, or $0.02 per diluted share, compared with a net loss of $7.7M, or $(0.11) per share, a year earlier. Adjusted EBITDA was stable at $51.2M, while adjusted diluted earnings per share increased to $0.18 from $0.04. System-wide total procedures grew, with advanced procedures expanding faster than overall volumes, supporting management’s view of sustained, profitable growth.
Lumexa Imaging Holdings, Inc. is asking stockholders to elect three Class I directors—Lee Cooper, Brian Regan and CEO Caitlin Zulla—to terms running until the 2029 annual meeting, and to ratify PwC as independent auditor for the year ending December 31, 2026.
The 2026 annual meeting will be held virtually on June 10, 2026 at 8:30 a.m. Eastern Time via webcast at www.proxydocs.com/LMRI, with advance online registration required by June 5, 2026. Holders of the company’s 96,110,039 outstanding common shares as of April 13, 2026 may vote.
The proxy also details board structure, committee memberships and independence, director retainers and annual equity awards, and 2025 executive pay. CEO Caitlin Zulla received a $750,000 salary, a $3.5 million signing bonus, equity awards tied to stock-price hurdles and a 2025 bonus based on Adjusted EBITDA and strategic goals.
Lumexa Imaging Holdings, Inc. reported that on April 8, 2026 it held a meeting and site visit where it reiterated its previously disclosed full year 2026 guidance. The company stated this information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act unless specifically designated or incorporated by reference.
Lumexa Imaging Holdings, Inc. reports full-year 2025 results as a newly public, national diagnostic imaging platform. The company operated 188 outpatient centers across 13 states as of December 31, 2025, supported by roughly 102,000 referring physicians from more than 32,000 practices.
Consolidated revenue reached $1.023 billion for 2025, up 7.8% from 2024, while system-wide revenue, which includes unconsolidated joint ventures, also grew 8.2%. Lumexa recorded a 2025 net loss of $47.1 million but generated Adjusted EBITDA of $230.2 million, a 22.5% margin, reflecting scale and operating leverage.
During 2025 the company completed an IPO of 25,000,000 common shares, raising approximately $427 million in net proceeds. Advanced imaging, particularly MRI and CT, was a key driver, accounting for 52% of consolidated revenue and 63% of system-wide revenue. Management highlights strong patient satisfaction, expansive health system joint ventures, and growing use of third-party AI and teleradiology (Connexia) as core competitive strengths.
Lumexa Imaging Holdings, Inc. reported preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025 and reiterated its full-year 2026 guidance. Full-year 2025 total revenues rose to $1,023,081 thousand from $948,869 thousand, while net loss narrowed to $47,104 thousand from $94,099 thousand. Adjusted EBITDA increased to $230,154 thousand from $200,839 thousand, reflecting stronger operating performance. Basic and diluted loss per share improved to $0.66 from $1.35. Outpatient volumes grew, with consolidated total procedures up 4.6% for 2025 and consolidated advanced procedures up 7.8%. The company strengthened its balance sheet: cash and cash equivalents increased to $58,828 thousand from $26,131 thousand, and long-term debt (less current maturities) declined to $819,029 thousand from $1,185,080 thousand, supported by initial public offering proceeds of $434,750 thousand.
Lumexa Imaging Holdings, Inc. released preliminary, unaudited fourth quarter and full year 2025 results and issued 2026 guidance. For 2025, GAAP net loss was $43,768 thousand, improving from $94,099 thousand in 2024, while Adjusted EBITDA rose to $229,029 thousand from $200,839 thousand. Fourth quarter 2025 Adjusted EBITDA was $62,625 thousand, up from $53,742 thousand a year earlier, with management citing expected Adjusted EBITDA growth of at least 14%. System-wide total procedures reached 3,972,228 in 2025, with advanced procedures growing and PET volumes up 17.0% on a consolidated basis and 13.5% system-wide. The company highlights expansion of de novo centers, one acquisition, new joint venture partnerships, and early adoption of AI-powered breast arterial calcification assessments as drivers of growth.
Lumexa Imaging Holdings, Inc. reported that its Principal Accounting Officer, Walker James Edward Jr., acquired 12,414 shares of common stock in the form of restricted stock units. The grant carried a price of $0.0000 per share, indicating it was an equity award rather than an open-market purchase.
Each RSU represents the contingent right to receive one share of Lumexa common stock. The RSUs vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, conditioned on Mr. Walker’s continued service with the company. Following this award, his directly owned common stock and RSUs total 17,346 shares.